Changes in the expression of novel coagulation and fibrinolytic markers in chronic kidney disease

Yu Haidong; Tian Yun; Zhang Lei; Wang Huan; Chen Chu

doi:10.13406/j.cnki.cyxb.003333

您当前的位置：

首页 >

文章列表页 >

Changes in the expression of novel coagulation and fibrinolytic markers in chronic kidney disease

Clinical research | 更新时间：2025-10-21

- Changes in the expression of novel coagulation and fibrinolytic markers in chronic kidney disease
- Journal of Chongqing Medical University Vol. 48, Issue 9, Pages: 1138-1142(2023)
- 作者机构：
  
  1.华北医疗健康集团峰峰总医院检验科,邯郸 056201
  2.陕西省中医医院肾病科,西安 710000
  3.西安交通大学第二附属医院检验科,西安 710004
  4.陕西省中医医院检验科,西安 710000
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.003333
  CLC： R55
- Received：07 March 2023，
  
  Revised：2023-04-06，
  
  Accepted：10 May 2023，
  
  Published：28 September 2023
- 稿件说明：
移动端阅览
于海东,田耘,张磊,等.新型凝血、纤溶标志物在慢性肾脏疾病中的表达变化分析[J].重庆医科大学学报,2023,48(9):1138-1142.

Yu Haidong,Tian Yun,Zhang Lei,et al.Changes in the expression of novel coagulation and fibrinolytic markers in chronic kidney disease[J].Journal of Chongqing Medical University,2023,48(9):1138-1142.
于海东,田耘,张磊,等.新型凝血、纤溶标志物在慢性肾脏疾病中的表达变化分析[J].重庆医科大学学报,2023,48(9):1138-1142. DOI： 10.13406/j.cnki.cyxb.003333.

Yu Haidong,Tian Yun,Zhang Lei,et al.Changes in the expression of novel coagulation and fibrinolytic markers in chronic kidney disease[J].Journal of Chongqing Medical University,2023,48(9):1138-1142. DOI： 10.13406/j.cnki.cyxb.003333.

摘要

目的

分析慢性肾病（chronic kidney disease，CKD）患者血浆凝血、纤溶标志物的表达变化趋势，为CKD相关凝血性疾病的诊断和治疗提供依据。

方法

从2021年5月到2022年5月就诊于陕西省中医医院的CKD患者和体检人员中根据纳入标准获得CKD患者123名，依据肾小球滤过率（estimated glomerular filtration rate，eGFR）分组，健康体检者40名设为对照组（health control，HC组），分别检测凝血酶调节蛋白（thrombomodulin，TM）、凝血酶-抗凝血酶复合物（thrombin-antithrombin complex，TAT）、纤溶酶-α2抗纤溶酶复合物（plasmin-α

-antiplasmin complex，PIC）、组织型纤溶酶原激活物抑制剂-1复合物（tissue plasminogen activator inhibitor complex，t-PAIC）、凝血酶原时间（prothrombin time，PT）、活化部分凝血酶原时间（activated partial thromboplastin time，APTT）、凝血酶时间（thrombin time，TT）、纤维蛋白原（fibrinogen，FIB）、纤维蛋白降解产物［fibrin（-ogen） degradation products，FDP］、D-二聚体（D-dimer，DD）水平以及白蛋白、血肌酐（serum creatinine，SCr a）及尿素氮（blood urea nitrogen，BUN）的表达水平。

结果

PT、APTT和TT在各组间的差异无统计学意义（

0.05），CKD组中FIB、DD和TAT高于HC组（

0.001）；DD在CKD5期高于CKD1、2期（

0.05）；FDP在CKD2-5期均高于HC组（

0.05）且CKD5期高于CKD1、2期；PIC在CKD 3-5期高于HC组，CKD4期高于CKD1、2期（

0.001）；tPAIC在CKD1-4期高于HC组（

0.05）；TM在CKD2-5期高于HC组，CKD4-5期高于其他分期（

0.001）；CKD各组TAT/PIC比值高于HC组，CKD1-3组与HC组的差异有统计学意义（

0.001），TAT/PIC对CKD和HC的鉴别进行受试者工作曲线（receiver operating characteristic curve，ROC）分析，曲线下面积（area under curve，AUC）为0.716。

结论

CKD患者体内普遍存在高凝状态，新凝血标志物反映凝血功能变化的能力更优秀。

Abstract

Objective

To investigate the changing trend of the expression of plasma coagulation and fibrinolytic markers in patients with chronic kidney disease（CKD），and to provide a basis for the diagnosis and treatment of CKD-related coagulopathies.

Methods

According to the inclusion criteria，123 patients with CKD were selected from the CKD patients who attended Shaanxi Provincial Hospital of Traditional Chinese Medicine from May 2021 to May 2022，and they were divided into groups based on estimated glomerular filtration rate；40 healthy controls（HCs） were selected from the individuals who underwent physical examination and were established as HC group. Related coagulation and fibrinolytic markers were measured，i.e.，thrombomodulin（TM），thrombin-antithrombin complex （TAT），fibrin-α2 antifibrinolytic complex（PIC），tissue-type fibrinogen activator inhibitor-1 complex（t-PAIC），prothrombin time （PT），activated partial thromboplastin time（APTT），thrombin time （TT），fibrinogen（FIB），fibrinogen degradation product（FDP），and D-dimer（DD），as well as the expression levels of albumin，serum creatinine（SCr），and blood urea nitrogen（BUN）.

Results

There were no significant differences in PT，APTT，and TT between groups（

0.05），and the CKD group had significantly higher FIB，DD，and TAT than the HC group （

0.001）. The level of DD in stage 5 CKD was significantly higher than that in stage 1/2 CKD（

0.05）. The level of FDP in stage 2-5 CKD was significantly higher than that in the HCs（

0.05），and the level of FDP in stage 5 CKD was significantly higher than that in stage 1/2 CKD. PIC in stage 3-5 CKD was significantly higher than that in the HCs，and PIC in stage 4 CKD was significantly higher than that in stage 1/2 CKD（

0.001）. The level of t-PAIC in stage 1-4 CKD was significantly higher than that in the HCs（

0.05）. TM in stage 2-5 CKD was significantly higher than that in the HCs，and TM in stage 4-5 CKD was significantly higher than that in the other stages（

0.001）. The CKD groups had a significantly higher TAT/PIC ratio than the HC group，with a significant difference between stage 1-3 CKD and the HCs（

0.001）. The receiver operating characteristic（ROC） curve analysis of TAT/PIC ratio showed an area under the ROC curve of 0.7

16 in differentiating CKD from HCs.

Conclusion

Hypercoagulability is prevalent in CKD patients，and novel coagulation markers have a good ability to reflect the changes in coagulation function.

关键词

Keywords

references

Yapa HE ， Purtell L ， Chambers S ， et al . The relationship between chronic kidney disease，symptoms and health-related quality of life：a systematic review [J ] . J Ren Care ， 2020 ， 46 （ 2 ）： 74 - 84 .

刘旭利，程庆砾，刘海波，等 . 社区高龄男性慢性肾脏病患者的营养和心理健康状况调查 [J ] . 中华全科医师杂志， 2014 ， 13 （ 1 ）： 32 - 36 .

Liu XL ， Cheng QL ， Liu HB ， et al . A survey of nutritional and mental health condition in elderly community-dwelling males with chronic kidney disease [J ] . Chin J Gen Pract ， 2014 ， 13 （ 1 ）： 32 - 36 .

张黎蕾，夏　茂，夏永泉，等 . 慢性肾脏病伴心脑血管病患者凝血、抗凝及纤溶指标变化分析 [J ] . 临床检验杂志， 2020 ， 38 （ 11 ）： 854 - 857 .

Zhang LL ， Xia M ， Xia YQ ， et al . Changes of coagulation，anticoagulation and fibrinolysis indexes in chronic kidney disease patients complicated with cardiocerebrovascular diseases [J ] . Chin J Clin Lab Sci ， 2020 ， 38 （ 11 ）： 854 - 857 .

Kidney Disease ： Improving Global Outcomes（KDIGO）Diabetes Work Group . KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease [J ] . Kidney Int ， 2020 ， 98 （ 4S ）： S1 - S115 .

Hill NR ， Fatoba ST ， Oke JL ， et al . Global prevalence of chronic kidney disease--A systematic review and Meta-analysis [J ] . PLoS One ， 2016 ， 11 （ 7 ）： e0158765 .

张丽新，唐筱婉，刘　芳，等 . 慢性肾脏病静脉血栓栓塞症抗凝治疗新进展 [J ] . 临床药物治疗杂志， 2021 ， 19 （ 9 ）： 1 - 7 .

Zhang LX ， Tang XW ， Liu F ， et al . New progress in anticoagulation therapy for venous thromboembolism in patients with chronic kidney disease [J ] . Clin Med J ， 2021 ， 19 （ 9 ）： 1 - 7 .

何　娟，雍珍珠，赵卫红 . 老年肾病综合征患者的抗凝治疗 [J ] . 中华老年医学杂志， 2021 ， 40 （ 10 ）： 1241 - 1244 .

He J ， Yong ZZ ， Zhao WH . Anticoagulant therapy in elderly patients with nephrotic syndrome [J ] . Chin J Geriatr ， 2021 ， 40 （ 10 ）： 1241 - 1244 .

李　臻，李　贞，陈伟琴，等 . 血浆纤溶标志物在原发性膜性肾病疾病进展中的变化 [J ] . 检验医学， 2020 ， 35 （ 1 ）： 25 - 28 .

Li Z ， Li Z ， Chen WQ ， et al . Changes of plasma fibrinolytic markers in idiopathic membranous nephropathy disease progress [J ] . Lab Med ， 2020 ， 35 （ 1 ）： 25 - 28 .

王　飙，赵和平，武翊伦，等 . 凝血-纤溶标志物对诊断创伤性骨折围手术期深静脉血栓的应用价值研究 [J ] . 现代医学， 2019 ， 47 （ 8 ）： 1023 - 1027 .

Wang B ， Zhao HP ， Wu YL ， et al . Application of coagulation-fibrinolytic marker to the diagnosis of deep vein thrombosis in the perioperative period of traumatic fracture [J ] . Mod Med J ， 2019 ， 47 （ 8 ）： 1023 - 1027 .

谢玉茹，廖　扬，黄东泉，等 . 早期血栓分子标记物检测在骨折患者围术期的临床应用 [J ] . 解放军医学院学报， 2020 ， 41 （ 2 ）： 170 - 173 .

Xie YR ， Liao Y ， Huang DQ ， et al . Perioperative changes of early thrombosis molecular markers in fracture patients [J ] . Acad J Chin PLA Med Sch ， 2020 ， 41 （ 2 ）： 170 - 173 .

许彬彬，苟泽辉，周　莉，等 . 创伤性骨折患者高密度脂蛋白水平与深静脉血栓相关性的研究 [J ] . 四川大学学报（医学版）， 2019 ， 50 （ 2 ）： 248 - 251 ．

Xu BB ， Gou ZH ， Zhou L ， et al . Low plasma high density lipoprotein-cholesterol level associated with deep vein thrombosis in traumatic fracture patients [J ] . J Sichuan Univ Med Sci Ed ， 2019 ， 50 （ 2 ）： 248 - 251 ．

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

⁰